Longwall Ventures

OrganOx Limited, founded in 2008 in Oxford, United Kingdom, specializes in developing devices for organ preservation and transplantation. The company's flagship product, Metra, is designed to store livers outside the body at normal body temperature, mimicking the human body's environment through continuous perfusion with oxygen-carrying red cells and nutrition. This technology aims to prevent organ deterioration by maintaining physiological conditions such as bile production, glucose metabolism, and pH levels. OrganOx focuses on research and development for liver testing and transplantation, providing solutions to preserve livers before transplantations.

Biofidelity Ltd., established in 2019 and based in Cambridge, UK, specializes in the research and development of molecular diagnostic assays. These assays are designed to rapidly detect specific DNA sequences, with a focus on applications in oncology, prenatal testing, infectious diseases, and organ transplant monitoring. The company's mission is to enhance and prolong patients' lives through early disease detection and targeted treatments.

Wayland Additive is a company based in Huddersfield, United Kingdom, that specializes in the development, manufacture, and distribution of metal additive manufacturing 3D printing machines. Founded in 2019, Wayland Additive focuses on advancing electron beam 3D printing technology to serve industrial end-users, particularly in the aerospace and medical sectors. The company's machines are designed to provide exceptional process monitoring and control, enabling the use of super hard-wearing and high-temperature materials that are challenging to work with using traditional methods. By offering enhanced versatility and precision, Wayland Additive aims to support clients in achieving high-performance products across various industries, including aerospace, medical, energy, and tooling.

Lightcast Discovery Limited, founded in 2019 and based in Cambridge, United Kingdom, specializes in drug discovery through advanced microfluidic technology. The company focuses on developing new therapies and innovative products by leveraging its unique platform, which allows for the precise and flexible control of thousands of droplets. This capability enables the combination of various cells, reporters, and reagents to conduct complex workflows without manual cell manipulation. By collaborating with major pharmaceutical companies and leading academic institutions, Lightcast Discovery seeks to enhance complex cell analysis and facilitate the discovery of new clinical approaches.

Wayland Additive is a company based in Huddersfield, United Kingdom, that specializes in the development, manufacture, and distribution of metal additive manufacturing 3D printing machines. Founded in 2019, Wayland Additive focuses on advancing electron beam 3D printing technology to serve industrial end-users, particularly in the aerospace and medical sectors. The company's machines are designed to provide exceptional process monitoring and control, enabling the use of super hard-wearing and high-temperature materials that are challenging to work with using traditional methods. By offering enhanced versatility and precision, Wayland Additive aims to support clients in achieving high-performance products across various industries, including aerospace, medical, energy, and tooling.

Caristo Diagnostics Limited is a pioneering company based in Oxford, United Kingdom, specializing in the development of artificial intelligence-driven software for cardiac diagnostics. Founded in 2018 as a spin-out from the University of Oxford, Caristo focuses on predicting and diagnosing coronary artery disease, heart attacks, strokes, and diabetes through its advanced imaging-based platforms. Its flagship product, the CaRi-Heart technology, utilizes AI algorithms to analyze routine cardiac computed tomography (CCTA) scans, enabling the measurement of the Fat Attenuation Index (FAI), a novel biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical information, including individual risk assessments and coronary plaque characterization. The technology has received CE Mark certification and is currently designated for research use in the U.S. Caristo's innovations have garnered significant validation in respected medical journals and have been supported by various government grants, demonstrating its potential to transform cardiac care by enhancing the prediction and prevention of heart-related events globally.

MicrofluidX Ltd is a London-based company established in 2018 that specializes in developing a cell bioprocessing platform specifically designed for autologous cell and gene therapy manufacturing. The company offers a microfluidic bioprocessing system that integrates various cell culture capabilities—including seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting—into a single closed system. This automated technology addresses key challenges in the field, such as process control, scalability, and cost, enabling biologists to efficiently conduct process development by experimenting with multiple cell culture conditions.

MIRICO Ltd. is a laser spectroscopy instrumentation company based in Oxford, United Kingdom, founded in December 2015. The company specializes in developing high-performance gas sensing technology using Laser Dispersion Spectroscopy. MIRICO's innovative instruments are designed for trace gas analysis and provide precise, real-time measurements of gas emissions, even in challenging weather conditions. Its offerings include stable isotope analyzers for space exploration and advanced monitoring solutions for applications in environmental monitoring, geochemistry, medical diagnosis, and oil and gas exploration. Through autonomous and continuous monitoring capabilities, MIRICO enables industries to track emissions effectively and gain insights into their operations, contributing to efforts aimed at achieving net-zero emissions and enhancing productivity. The company emerged as a spin-out from the Laser Spectroscopy Group at the STFC Rutherford Appleton Laboratory and is located on the Harwell Science & Innovation Campus.

Helio Display Materials is a developer of innovative perovskite-based materials aimed at enhancing display technology. The company focuses on creating materials that enable brighter and more colorful displays while significantly reducing power consumption. By leveraging metal halide perovskites, which can be synthesized using low-temperature processes and earth-abundant precursor materials, Helio aims to produce vibrant and efficient light-emitting technologies for televisions and displays. The company emphasizes collaboration with scientific and industry experts to expedite research and development, ensuring a strong scientific foundation for its intellectual property. Helio's mission is to improve display performance and efficiency, ultimately providing a superior visual experience.

Wayland Additive is a company based in Huddersfield, United Kingdom, that specializes in the development, manufacture, and distribution of metal additive manufacturing 3D printing machines. Founded in 2019, Wayland Additive focuses on advancing electron beam 3D printing technology to serve industrial end-users, particularly in the aerospace and medical sectors. The company's machines are designed to provide exceptional process monitoring and control, enabling the use of super hard-wearing and high-temperature materials that are challenging to work with using traditional methods. By offering enhanced versatility and precision, Wayland Additive aims to support clients in achieving high-performance products across various industries, including aerospace, medical, energy, and tooling.

Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, focused on creating innovative solutions that integrate prescription drugs with digital therapy. Founded by a team of healthcare professionals and scientists, the company aims to optimize drug dosing tailored to individual needs while incorporating linked behavioral therapy to enhance patient outcomes. Closed Loop Medicine is recognized as a leader in developing combination products that address chronic diseases, with current projects targeting hypertension and insomnia, among others. The company's approach emphasizes the importance of both patients and clinicians in the design and development of its offerings, ensuring that they meet real-world healthcare needs effectively.

Iothic is a developer of a decentralized platform that specializes in providing end-to-end, post-quantum resistant authentication and encryption solutions. The company's technology focuses on enabling secure, scalable, and robust authentication techniques that are compatible across various operating systems, communication protocols, and Internet of Things (IoT) stacks. By facilitating point-to-point quantum-resistant authentication, Iothic allows network providers to efficiently establish autonomous authentication services for a range of applications, from simple sensor networks to complex IoT systems. This innovation positions Iothic as a key player in enhancing security and interoperability in decentralized network environments.

Caristo Diagnostics Limited is a pioneering company based in Oxford, United Kingdom, specializing in the development of artificial intelligence-driven software for cardiac diagnostics. Founded in 2018 as a spin-out from the University of Oxford, Caristo focuses on predicting and diagnosing coronary artery disease, heart attacks, strokes, and diabetes through its advanced imaging-based platforms. Its flagship product, the CaRi-Heart technology, utilizes AI algorithms to analyze routine cardiac computed tomography (CCTA) scans, enabling the measurement of the Fat Attenuation Index (FAI), a novel biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical information, including individual risk assessments and coronary plaque characterization. The technology has received CE Mark certification and is currently designated for research use in the U.S. Caristo's innovations have garnered significant validation in respected medical journals and have been supported by various government grants, demonstrating its potential to transform cardiac care by enhancing the prediction and prevention of heart-related events globally.

Kinomica Limited is a research and diagnostics company focused on advancing medicine, particularly in cancer treatment. The company has developed KScan, a phosphoproteomic diagnostic platform designed to enhance treatment decisions for anticancer therapies. KScan enables clinicians to prescribe the most appropriate drugs for patients by measuring intracellular kinase activity and cell-signaling pathways in cells and tissues. Its advanced bioinformatics and analytical methods provide direct measurements of multiple kinases and comprehensive coverage of cell signaling networks. This innovative approach facilitates a better understanding of disease mechanisms and supports the identification of biomarkers, ultimately aiming to improve patient outcomes. Kinomica, formerly known as Pronostics Ltd., was incorporated in 2016 and is headquartered in Macclesfield, United Kingdom.

MicrofluidX Ltd is a London-based company established in 2018 that specializes in developing a cell bioprocessing platform specifically designed for autologous cell and gene therapy manufacturing. The company offers a microfluidic bioprocessing system that integrates various cell culture capabilities—including seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting—into a single closed system. This automated technology addresses key challenges in the field, such as process control, scalability, and cost, enabling biologists to efficiently conduct process development by experimenting with multiple cell culture conditions.

LettUs Grow Ltd. is a company based in Bristol, United Kingdom, founded in 2015, that specializes in aeroponic irrigation and control technology for indoor farming. The company develops innovative systems that enable plants to grow without soil, using a fine mist for watering and LED lighting for photosynthesis. Their modular, nozzle-free aeroponic hardware is designed to be easy to clean and fully automatable, which reduces the reliance on pesticides and minimizes operational costs. In addition to hardware, LettUs Grow provides software and data services that optimize farming practices, enhancing efficiency and sustainability while lowering the environmental impact of agriculture. The company is committed to transforming farming through technology, aiming to create a more sustainable and efficient agricultural industry.

Wayland Additive is a company based in Huddersfield, United Kingdom, that specializes in the development, manufacture, and distribution of metal additive manufacturing 3D printing machines. Founded in 2019, Wayland Additive focuses on advancing electron beam 3D printing technology to serve industrial end-users, particularly in the aerospace and medical sectors. The company's machines are designed to provide exceptional process monitoring and control, enabling the use of super hard-wearing and high-temperature materials that are challenging to work with using traditional methods. By offering enhanced versatility and precision, Wayland Additive aims to support clients in achieving high-performance products across various industries, including aerospace, medical, energy, and tooling.

Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, focused on creating innovative solutions that integrate prescription drugs with digital therapy. Founded by a team of healthcare professionals and scientists, the company aims to optimize drug dosing tailored to individual needs while incorporating linked behavioral therapy to enhance patient outcomes. Closed Loop Medicine is recognized as a leader in developing combination products that address chronic diseases, with current projects targeting hypertension and insomnia, among others. The company's approach emphasizes the importance of both patients and clinicians in the design and development of its offerings, ensuring that they meet real-world healthcare needs effectively.

Verdel Instruments Ltd specializes in the development of two-dimensional mass spectrometry (2DMS) equipment aimed at structural analysis and sequencing. Founded in 2018 and headquartered in Coventry, United Kingdom, the company provides advanced mass spectrometry technology that is utilized in analytical laboratories for the identification of key components and impurities in biopharmaceuticals, food, chemical products, and environmental samples. Its innovative technology allows for the fragmentation of various molecules while maintaining a correlation between each fragment and its precursor, significantly enhancing the structural elucidation process. This capability enables researchers to obtain comprehensive fragmentation datasets in seconds on standard bench-top mass spectrometers.

Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, focused on creating innovative solutions that integrate prescription drugs with digital therapy. Founded by a team of healthcare professionals and scientists, the company aims to optimize drug dosing tailored to individual needs while incorporating linked behavioral therapy to enhance patient outcomes. Closed Loop Medicine is recognized as a leader in developing combination products that address chronic diseases, with current projects targeting hypertension and insomnia, among others. The company's approach emphasizes the importance of both patients and clinicians in the design and development of its offerings, ensuring that they meet real-world healthcare needs effectively.

Caristo Diagnostics Limited is a pioneering company based in Oxford, United Kingdom, specializing in the development of artificial intelligence-driven software for cardiac diagnostics. Founded in 2018 as a spin-out from the University of Oxford, Caristo focuses on predicting and diagnosing coronary artery disease, heart attacks, strokes, and diabetes through its advanced imaging-based platforms. Its flagship product, the CaRi-Heart technology, utilizes AI algorithms to analyze routine cardiac computed tomography (CCTA) scans, enabling the measurement of the Fat Attenuation Index (FAI), a novel biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical information, including individual risk assessments and coronary plaque characterization. The technology has received CE Mark certification and is currently designated for research use in the U.S. Caristo's innovations have garnered significant validation in respected medical journals and have been supported by various government grants, demonstrating its potential to transform cardiac care by enhancing the prediction and prevention of heart-related events globally.

Oxford Space Systems Limited is a Harwell, United Kingdom-based company that specializes in the development and manufacturing of deployable hardware structures for space environments. Founded in 2013, the company has gained recognition for its innovative designs, including deployable antennas, panels, hinge systems, and composite linear boom systems. Utilizing advanced techniques such as origami and proprietary materials, Oxford Space Systems creates solutions that are lighter, more efficient, and cost-effective compared to traditional alternatives, catering to the global satellite industry. The company's AstroTube Boom set a record for the fastest product development from concept to successful deployment in under 30 months. With a team of 18 professionals, combining diverse backgrounds and over a century of collective experience in the space sector, Oxford Space Systems has engaged in various collaborative projects with leading European satellite manufacturers and has secured commercial contracts across Asia and the US. The company operates from a state-of-the-art facility within the Harwell Space Cluster, equipped to meet the security requirements necessary for defense and security contracts.

MIRICO Ltd. is a laser spectroscopy instrumentation company based in Oxford, United Kingdom, founded in December 2015. The company specializes in developing high-performance gas sensing technology using Laser Dispersion Spectroscopy. MIRICO's innovative instruments are designed for trace gas analysis and provide precise, real-time measurements of gas emissions, even in challenging weather conditions. Its offerings include stable isotope analyzers for space exploration and advanced monitoring solutions for applications in environmental monitoring, geochemistry, medical diagnosis, and oil and gas exploration. Through autonomous and continuous monitoring capabilities, MIRICO enables industries to track emissions effectively and gain insights into their operations, contributing to efforts aimed at achieving net-zero emissions and enhancing productivity. The company emerged as a spin-out from the Laser Spectroscopy Group at the STFC Rutherford Appleton Laboratory and is located on the Harwell Science & Innovation Campus.

Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, focused on creating innovative solutions that integrate prescription drugs with digital therapy. Founded by a team of healthcare professionals and scientists, the company aims to optimize drug dosing tailored to individual needs while incorporating linked behavioral therapy to enhance patient outcomes. Closed Loop Medicine is recognized as a leader in developing combination products that address chronic diseases, with current projects targeting hypertension and insomnia, among others. The company's approach emphasizes the importance of both patients and clinicians in the design and development of its offerings, ensuring that they meet real-world healthcare needs effectively.

Base4 specializes in advancing state-of-the-art technologies for single-molecule analysis. The company is dedicated to developing innovative microdroplet-based sequencing technology that enables pathogen screening and DNA analysis. This technology generates long reads from individual DNA molecules without requiring initial amplification, providing users with the ability to understand and predict diseases more effectively. Base4's solutions aim to produce cheaper, more accurate, and meaningful sequencing data for large populations at a reduced cost.

Arquer Diagnostics Ltd. is a diagnostics company specializing in the design, development, and commercialization of non-invasive immunoassay diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring specific substances in body fluids, including a CE-marked ELISA kit for Mcm5, which is used in hospital pathology laboratories. Additionally, Arquer provides a point-of-care system that includes a robust reader instrument and disposable cartridges, facilitating the use of its tests in urology clinics, hospital laboratories, and general practice surgeries. Founded in 2005 and based in Sunderland, United Kingdom, Arquer Diagnostics aims to enhance cancer diagnosis and monitoring through its innovative technology, which detects a protein linked to the MCM5 gene, improving the accuracy and reliability of test results for patients and clinicians.

OxSonics Therapeutics is a biotechnology company focused on advancing anti-cancer therapies through its innovative SonoTran platform. This proprietary technology enhances the delivery and effectiveness of anti-cancer agents by improving their distribution within solid tumors, thereby increasing treatment efficacy and potentially reducing toxicity. Unlike traditional methods that often require drug reformulation, SonoTran employs a drug-agnostic approach that allows for the co-administration of particles with anti-cancer drugs, facilitating a localized pumping effect that enhances drug penetration throughout the tumor. Developed from cutting-edge research at the University of Oxford's Institute of Biomedical Engineering, SonoTran is designed to integrate seamlessly into existing oncology clinical workflows, providing real-time visualization for healthcare professionals as they treat patients. Headquartered in Oxford, UK, OxSonics aims to transform cancer treatment by addressing the significant challenges presented by solid tumors.

Keit Ltd. is a company specializing in the design and manufacture of advanced spectrometers and related instruments, catering to a wide range of applications from ultraviolet to far infrared rays. Incorporated in 2012 and headquartered in Didcot, United Kingdom, Keit is known for its innovative microFTS® design, a Fourier Transform Infrared (FTIR) spectrometer that is notably smaller, lighter, and more rugged than existing systems. Originally developed for space applications, the microFTS® is capable of operating in extreme environments and sets a new standard for real-time liquid-state analyses across various industries, including Pharmaceutical, Chemical, Oil & Gas, and Food & Beverage. Keit's products are also utilized for measuring signal levels, near line vibrations, and analyzing gas or liquid-borne species.

MIRICO Ltd. is a laser spectroscopy instrumentation company based in Oxford, United Kingdom, founded in December 2015. The company specializes in developing high-performance gas sensing technology using Laser Dispersion Spectroscopy. MIRICO's innovative instruments are designed for trace gas analysis and provide precise, real-time measurements of gas emissions, even in challenging weather conditions. Its offerings include stable isotope analyzers for space exploration and advanced monitoring solutions for applications in environmental monitoring, geochemistry, medical diagnosis, and oil and gas exploration. Through autonomous and continuous monitoring capabilities, MIRICO enables industries to track emissions effectively and gain insights into their operations, contributing to efforts aimed at achieving net-zero emissions and enhancing productivity. The company emerged as a spin-out from the Laser Spectroscopy Group at the STFC Rutherford Appleton Laboratory and is located on the Harwell Science & Innovation Campus.

User Replay Limited is a company that specializes in digital customer experience analytics software solutions. Founded in 2009 and headquartered in Reading, United Kingdom, it provides an integrated customer experience platform that leverages machine learning to help businesses discover and address issues in customer interactions. User Replay’s software tracks users' journeys on websites, identifying conversion barriers such as usability issues, technical problems, and confusing business logic. By analyzing the impact of these barriers on conversion rates, the platform enables targeted user experience improvements that can lead to measurable increases in sales. The company's solutions, which also support enhanced customer service and fraud prevention, are utilized by over 20 prominent brands across various sectors, including financial services, insurance, retail, and travel, in markets throughout the United States, United Kingdom, Europe, and beyond.

Oxford Cancer Biomarkers is a company focused on the development and commercialization of a range of biomarker tests specifically for colorectal cancer, aimed at enhancing personalized medicine in oncology. Closely associated with the Institute of Cancer Medicine at Oxford University, where its founders conduct leading research in translational cancer science, the company has established partnerships with pharmaceutical firms to leverage its discovery platforms, CancerNav and ToxNav, in creating companion diagnostic tests for emerging drugs. The tests provided by Oxford Cancer Biomarkers assess dihydropyridine dehydrogenase deficiency, identify variants linked to partial dihydropyrimidine deficiency, and evaluate the risk of potential toxicity, allowing healthcare providers to analyze resected tissue samples and predict relapse risk for patients more effectively.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

Arquer Diagnostics Ltd. is a diagnostics company specializing in the design, development, and commercialization of non-invasive immunoassay diagnostic tests for bladder and prostate cancer. The company offers an enzyme-linked immunosorbent assay (ELISA) for measuring specific substances in body fluids, including a CE-marked ELISA kit for Mcm5, which is used in hospital pathology laboratories. Additionally, Arquer provides a point-of-care system that includes a robust reader instrument and disposable cartridges, facilitating the use of its tests in urology clinics, hospital laboratories, and general practice surgeries. Founded in 2005 and based in Sunderland, United Kingdom, Arquer Diagnostics aims to enhance cancer diagnosis and monitoring through its innovative technology, which detects a protein linked to the MCM5 gene, improving the accuracy and reliability of test results for patients and clinicians.

Sensiia Limited is a company based in Cambridge, United Kingdom, that specializes in the manufacture of sensor-based fertility wearable devices. Its flagship product, DuoFertility, is designed to track and predict female ovulation cycles while providing personalized support from fertility experts. This innovative system identifies the most fertile window up to 10 days in advance, allowing users to plan their schedules with greater confidence. DuoFertility has been clinically validated, demonstrating effectiveness comparable to that of an IVF cycle. Founded in 2006 and formerly known as Cambridge Temperature Concepts Limited, Sensiia focuses on delivering a natural and data-driven approach to fertility management, leveraging continuous monitoring and analytics to enhance user outcomes in reproductive health.

Momentum Bioscience Ltd is a biotechnology company specializing in the development of rapid diagnostic tests for critical clinical specimens. Established in 2005 and based in Cardiff, United Kingdom, the company utilizes its innovative Enzyme Mediated Amplification (EMA) technology to enable the universal detection of viable bacteria and fungi in under two hours, significantly reducing the time compared to traditional laboratory methods that can take 1 to 5 days. Momentum Bioscience's products are particularly valuable in neonatal care, emergency care, and critical care settings, as they specifically measure viable organisms, ensuring accurate detection of infections in blood and other normally sterile body fluids. The company is focused on advancing its suite of related technologies to enhance pathogen detection and support microbiology laboratories.

Oxford Space Systems Limited is a Harwell, United Kingdom-based company that specializes in the development and manufacturing of deployable hardware structures for space environments. Founded in 2013, the company has gained recognition for its innovative designs, including deployable antennas, panels, hinge systems, and composite linear boom systems. Utilizing advanced techniques such as origami and proprietary materials, Oxford Space Systems creates solutions that are lighter, more efficient, and cost-effective compared to traditional alternatives, catering to the global satellite industry. The company's AstroTube Boom set a record for the fastest product development from concept to successful deployment in under 30 months. With a team of 18 professionals, combining diverse backgrounds and over a century of collective experience in the space sector, Oxford Space Systems has engaged in various collaborative projects with leading European satellite manufacturers and has secured commercial contracts across Asia and the US. The company operates from a state-of-the-art facility within the Harwell Space Cluster, equipped to meet the security requirements necessary for defense and security contracts.

Oxford PV is a company based in Oxford, United Kingdom, founded in 2010 by Henry Snaith and Kevin Arthur. It specializes in the development and commercialization of thin-film perovskite solar cells, which are designed to be printed directly onto silicon solar cells, CIGS solar cells, or glass. The company's innovative technology enhances photovoltaic performance by efficiently capturing specific parts of the solar spectrum, providing a low-cost and lightweight alternative for energy generation. Oxford PV aims to contribute significantly to the growth of renewable energy globally through its advanced solar cell solutions.

OrganOx Limited, founded in 2008 in Oxford, United Kingdom, specializes in developing devices for organ preservation and transplantation. The company's flagship product, Metra, is designed to store livers outside the body at normal body temperature, mimicking the human body's environment through continuous perfusion with oxygen-carrying red cells and nutrition. This technology aims to prevent organ deterioration by maintaining physiological conditions such as bile production, glucose metabolism, and pH levels. OrganOx focuses on research and development for liver testing and transplantation, providing solutions to preserve livers before transplantations.

Crysalin Limited is a research and development company based in London, United Kingdom, founded in June 2007. It specializes in crysalin lattice technology, which has been developed from patented research conducted at the Oxford University Laboratory of Molecular Biophysics since 2002. The company's primary focus is on crysalins, a protein-based nanotechnology that significantly enhances protein structure determination, particularly for challenging macromolecular targets such as membrane proteins and flexible soluble proteins. By imposing order on these complex structures, crysalins enable advanced imaging techniques like X-ray and electron microscopy to accurately resolve three-dimensional molecular structures. In addition to protein structure determination, Crysalin's technology holds potential applications in biosensor development and optoelectronics, expanding its impact in the field of molecular research.

Diamond Microwave Devices Ltd. specializes in the development of semiconductor devices utilizing chemical vapor deposition (CVD) diamond technology. Founded in 2006 and headquartered in Leeds, United Kingdom, the company focuses on creating devices that serve both civil and defense applications, particularly in microwave power amplifiers and transmitters. As a subsidiary of Element Six (Pty) Ltd., Diamond Microwave Devices is positioned at the forefront of innovation in high-performance microwave technology.